High-Throughput Validation for AI-Designed Antibodies

Artificial Intelligence (AI) is reshaping antibody discovery, enabling researchers to design and prioritize vast numbers of candidate sequences in a fraction of the time required by traditional approaches.¹ However, generating candidates is only part of the challenge; to translate computational predictions into meaningful biological insights, researchers must both rapidly produce antibodies and generate robust experimental data at a comparable scale. To this end, high-throughput workflows help scientists combine parallel antibody expression with streamlined developability assessment, generating datasets to guide candidate prioritization and iterative AI model refinement.

High-throughput antibody production is a critical enabler of rapid design-build-test-learn cycles. Efficient expression approaches, including well-established mammalian transient expression and rapid cell-free synthesis, support parallel production across diverse antibody formats, translating large panels of AI-designed sequences into physical, testable molecules.

Equally important is systematic characterization of the resulting antibodies. Early, multidimensional developability profiling across attributes such as solubility, stability, and aggregation propensity enables rapid candidate comparison and identification of potential liabilities. The resulting standardized datasets support candidate ranking and selection while providing valuable feedback for AI model refinement and subsequent design cycles.

Bridging the gap between AI design and experimental validation calls for streamlined sequence-to-data workflows. One example of this approach is Sino Biological’s integrated high-throughput platform spanning antibody production, developability assessment, and AI-ready data generation. Dual production routes offer proven mammalian transient expression, backed by more than 100,000 delivered projects, alongside ultra-fast cell-free synthesis capable of completing expression within three hours. The platform supports rapid production of thousands of antibodies across diverse formats, including scFvs, VHHs, Fabs, minibinders, IgGs, and bispecifics. Downstream, more than 20 developability assays profile key attributes such as self-association, hydrophobicity, thermal stability, and polyreactivity, generating structured, high-quality datasets. The platform enables high-throughput wet-lab validation from sequence to data in as little as three days, supporting rapid iteration in AI-driven antibody discovery.

Explore this integrated high-throughput platform for antibody production and developability assessment.